Robert L Redner MD
Professor, Medicine, University of Pittsburgh School of Medicine
Join to View Full Profile
5115 Centre AvenueUpmc Cancer PavillionPittsburgh, PA 15232
Phone+1 412-692-4724
Dr. Redner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
Harvard Medical SchoolClass of 1980
Certifications & Licensure
CA State Medical License 1983 - Present
PA State Medical License 1991 - 2026
MD State Medical License 1984 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
- A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Jan 01
- Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.Kevin Quann, Konstantinos Lontos, Alison Sehgal, Anastasios Raptis, Annie Im
Haematologica. 2024-12-01 - 3 citationsBeat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Fieke W Hoff, William G Blum, Ying Huang, Rina Li Welkie, Ronan T Swords
Blood Advances. 2024-10-22 - 1 citationsPhase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.Annie Im, Kevin Quann, Mounzer Agha, Anastasios Raptis, Robert L Redner
American Journal of Hematology. 2024-03-01
Grant Support
- Characterization Of A Novel Translocation Product In APLNational Cancer Institute2006–2009
- Calcitriol &Dexamethasone For Myelodysplastic SyndromesFood And Drug Administration2004
- Vitamin D And Dexamethasone In Myelodysplastic SyndromesNational Cancer Institute2002–2003
- Novel Translocation Product In APLNational Cancer Institute1995–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
